Cardiovascular Optimization: A Protocol Beyond Statins
Atherosclerosis has four main drivers and lipids are one of them. A protocol that addresses only lipids leaves most of the modifiable risk untouched.
The Short Answer
The causal picture in atherosclerotic cardiovascular disease is reasonably well established: apolipoprotein B particle burden, blood pressure, smoking and glycaemic dysfunction do most of the work, with inflammatory contribution and lipoprotein(a) as significant additional factors. Statins address one of them, effectively. A protocol organised around all of them covers considerably more modifiable risk, and three of the four respond to things that are not medication.
Driver One: Apolipoprotein B Particle Burden
The causal exposure in atherosclerosis is the number of atherogenic particles entering the arterial wall over time, not the cholesterol they carry. Each atherogenic particle, LDL, VLDL, IDL, remnants and Lp(a), carries exactly one apolipoprotein B molecule, so apoB counts particles directly.
This matters because LDL cholesterol and apoB can diverge. A person with small dense particles has more particles per unit of cholesterol, so their apoB is higher than their LDL cholesterol implies, and their risk tracks the apoB. This pattern is common in insulin resistance, which is why Pillar 4 problems cluster.
What lowers apoB: reducing saturated fat intake modestly; soluble fibre; plant sterols; weight loss where adiposity is a factor; and, substantially, statins, ezetimibe and PCSK9 inhibitors where indicated. The medication effect is an order of magnitude larger than the dietary effect, which is a fact worth stating plainly rather than working around.
The exposure is cumulative over decades, which is the argument for acting earlier rather than at a threshold. It is also why a 35-year-old with elevated apoB has a different problem from a 70-year-old with the same value.
Driver Two: Blood Pressure
Blood pressure has among the strongest causal evidence of any cardiovascular risk factor, and it is routinely under-measured and under-addressed in optimisation contexts that focus on lipids.
Measure it properly. Clinic readings are frequently inaccurate. Home measurement, seated with back supported and arm at heart level, after five minutes of rest, twice each morning and evening for a week, with the first day discarded, gives a far better estimate. A validated upper-arm device is required; wrist devices are less reliable.
What lowers it: weight loss, aerobic exercise, sodium reduction with attention to processed food rather than the salt cellar, potassium from food, alcohol reduction, and addressing sleep-disordered breathing where present. Each effect is modest and they are additive.
Where medication belongs. Sustained elevation above threshold is a clinical situation with strong outcome evidence for medication, and the decision belongs with a clinician. Deferring it while pursuing lifestyle measures for years is a common and consequential error.
Sleep-disordered breathing deserves specific mention because it causes resistant hypertension and is frequently missed. Blood pressure that will not respond is a prompt to consider it.
Driver Three: Glycaemic Function and Insulin Resistance
| Marker | What it tells you | Note |
|---|---|---|
| HbA1c | Average glycaemia over roughly three months | Affected by red cell turnover, anaemia and haemoglobin variants |
| Fasting glucose | Late-appearing signal | Rises after insulin resistance is well established |
| Fasting insulin | Earlier signal of insulin resistance | Assay variability; useful as a trend |
| Triglyceride to HDL ratio | Practical insulin resistance proxy | Cheap, computed from a standard lipid panel |
| Waist circumference | Visceral adiposity proxy | Better than BMI for this purpose |
| Continuous glucose monitoring | Post-meal excursions and variability | Interpretation in non-diabetic use is unsettled |
Insulin resistance is upstream of much of the rest of this Pillar. It raises triglycerides, lowers HDL, shifts particles toward small dense LDL, raises blood pressure and raises inflammatory markers. Addressing it improves several markers at once, which is why it is the highest-leverage target for most people.
What addresses it: resistance training and aerobic volume, visceral fat reduction, adequate sleep, reducing refined carbohydrate and ultra-processed food, and adequate protein to preserve lean mass. Nothing here is novel and all of it works.
Driver Four: The Fixed and Semi-Fixed Factors
Lipoprotein(a). Largely genetically determined, an independent causal risk factor, and unresponsive to diet or exercise. Around one in five people has an elevated level and most do not know, because it is rarely measured. A single measurement is usually sufficient for life. Elevated Lp(a) does not have a specific approved therapy yet, and it changes how aggressively the other factors should be addressed, which is the practical value of knowing.
Family history. Premature cardiovascular disease in a first-degree relative meaningfully raises risk and should prompt earlier and more thorough assessment.
Smoking. The largest single modifiable factor. Not a lifestyle nuance.
Age and sex. Non-modifiable and part of any risk calculation.
Chronic kidney disease and inflammatory conditions. Both raise risk independently and are frequently omitted from consumer risk framing.
The reason to know the fixed factors is calibration. A person with elevated Lp(a) and a family history has a materially different risk profile from someone with identical lipids and neither, and the same apoB level warrants different urgency.
Assembling the Protocol
Measure first, once, properly. ApoB, lipoprotein(a) once in a lifetime, HbA1c, fasting insulin, triglyceride to HDL ratio, hs-CRP, home blood pressure over a week, waist circumference and a cardiorespiratory fitness estimate. Add a coronary artery calcium score where risk is intermediate and a decision hinges on it, which is a clinical conversation.
Weeks 1 to 12. Establish aerobic volume and resistance training. Home blood pressure monitoring. Reduce ultra-processed food and alcohol. Raise fibre gradually toward 30 g daily. Get sleep-disordered breathing assessed if there is any suggestion of it.
Months 3 to 6. Visceral adiposity reduction if it is a factor. Omega-3 if triglycerides are elevated. Plant sterols and soluble fibre if apoB reduction is the goal without medication.
Month 6. Re-measure apoB, HbA1c, blood pressure and hs-CRP.
The clinical conversation, not deferred. If apoB remains elevated, blood pressure remains above threshold, Lp(a) is high, or there is a strong family history, that is a discussion about medication rather than a reason for a longer supplement trial. The outcome evidence for statins and antihypertensives in appropriate populations is among the strongest in medicine, and no combination of the above matches it.
The Honest Framing of Statins
Since this article is titled beyond statins, the position on them should be explicit rather than implied.
Statins reduce cardiovascular events substantially in appropriate populations, with an evidence base spanning decades and hundreds of thousands of participants. Muscle symptoms are the most common complaint and blinded trials suggest a large proportion of attributed symptoms are not caused by the drug, which does not mean nobody experiences them. New-onset diabetes risk is small and real. Ezetimibe, bempedoic acid and PCSK9 inhibitors exist for people who cannot tolerate statins or need further reduction.
Beyond statins means addressing the three drivers a statin does not: blood pressure, glycaemic function and inflammatory load, plus the fitness and body composition inputs that affect all of them. It does not mean instead of statins where they are indicated.
That distinction is where a great deal of cardiovascular wellness content goes wrong, and it is the difference between a protocol that adds to appropriate care and one that substitutes for it.
The AEONNN Perspective
Pillar 4 is upstream of much of the Matrix, and this protocol reflects that. Insulin resistance raises triglycerides, shifts particle size, raises blood pressure and raises inflammatory markers, so addressing it improves Pillar 3 and Pillar 10 markers alongside Pillar 4 ones. That is why AEONNN ranks glycaemic function as the highest-leverage target for most members rather than as one item among several.
The Consensus layer is decisive here in a way it rarely is. Guideline positions on blood pressure thresholds, apolipoprotein B as the preferred exposure measure and lipoprotein(a) measurement once in a lifetime are all clearer than the wellness discourse around them, and the platform follows the guidelines.
AEONNN states the statin position explicitly rather than by implication. Beyond statins means addressing the drivers a statin does not touch, and it does not mean instead of one where it is indicated. A platform whose recommendations sit alongside appropriate medical care has to say which is which, and the Real-Time User layer's contribution, home blood pressure and fitness trend, is more useful in support of that care than as an alternative to it.
Pillar Matrix mapping
Database Matrix layers
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Population Layer (UK Biobank, NHANES)
- Real-Time User Layer (wearable and adherence signals)
Frequently Asked
What are the main drivers of cardiovascular disease?
Apolipoprotein B particle burden, blood pressure, smoking and glycaemic dysfunction, with inflammatory contribution and lipoprotein(a) as significant additional factors. Statins address one of them.
Why is apoB better than LDL cholesterol?
ApoB counts atherogenic particles directly, since each carries exactly one apoB molecule. LDL cholesterol measures the cholesterol carried, and the two diverge when particles are small and dense.
How should blood pressure be measured?
At home with a validated upper-arm device, seated with back supported and arm at heart level, after five minutes rest, twice morning and evening for a week, discarding the first day.
What is the highest-leverage metabolic target?
Insulin resistance. It raises triglycerides, lowers HDL, shifts particles toward small dense LDL, raises blood pressure and raises inflammatory markers, so addressing it improves several markers at once.
Should I measure lipoprotein(a)?
Yes, once. It is largely genetic, an independent causal risk factor, unresponsive to diet or exercise, elevated in roughly one in five people, and rarely measured. It changes how aggressively other factors should be addressed.
Can I avoid statins with lifestyle and supplements?
Dietary and supplement effects on apoB are roughly an order of magnitude smaller than statin effects. Where a statin is indicated, no combination of lifestyle and supplements matches the outcome evidence.
What does beyond statins mean?
Addressing the drivers a statin does not: blood pressure, glycaemic function and inflammatory load, plus fitness and body composition. It does not mean instead of a statin where one is indicated.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.